In other words, GILD has come full circle on the QT-prolongation issue. After dickering with GS9190 for more than three years, GILD still doesn’t have what it considers an acceptable regimen for testing.
Sounds like a perfect partner for IDIX and its non-nuke candidate. And if GILD wants a nuke, IDIX fits there as well. VRUS could be an option also of course, but I wonder if Roche gets first dibs on VRUS' 2nd gen nukes. If so, I'd be surprised if they passed.
Market Data 
Markets 
AI
